Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
about
Virologic Tools for HCV Drug Resistance TestingResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsNew hepatitis C virus drug discovery strategies and model systemsSeed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B InteractionA quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsNovel permissive cell lines for complete propagation of hepatitis C virus.Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Productive homologous and non-homologous recombination of hepatitis C virus in cell culture.Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.Hepatitis C homolog in dogs with respiratory illnessProduction and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceHighly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entryCombination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term hostHepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents.Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolateUnderstanding the hepatitis C virus life cycle paves the way for highly effective therapies.Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture.Treatment failure with new hepatitis C drugs.Is genotype 3 of the hepatitis C virus the new villain?Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.
P2860
Q26774374-0A3B9100-052E-4029-B5F5-5C91FB0BAAFBQ26777408-19B40322-2CBE-4772-97EB-056CCF911798Q26851159-3377761C-DF30-4E0E-B404-6EE01B73AB8AQ27684710-A5FAB5C4-BF09-4F6E-8416-8C1119584F09Q28537708-F456B469-6CF4-405F-B444-BE6D62FD2B08Q28538891-9A1F5ED8-6F85-4095-9AB5-090B788FB68AQ33602824-8C272841-9CF3-494E-A473-D1B2B4A1C158Q33904328-BB02EF0E-61C8-4B1E-899E-59EA52AE5DE4Q34057584-07986871-E5A0-4241-90F8-F41DA32384E5Q34185949-B5AC7BB3-0330-4371-8281-5E5C82FCD6E2Q34288777-BBA90D72-86FB-4CC0-868B-B02CFA98E97FQ34332546-FD0E0255-519B-41FF-AB03-69DC279639C7Q34411617-62BDD82E-065D-40BE-AA55-02875C6F709BQ34416582-435D64CC-D264-4264-84CB-C32090636379Q34580799-9355C183-8F02-4E2F-9B29-4B214281BF89Q34649619-6B5F8F96-F3E8-4891-B3EB-82BAB3907A94Q34742954-D5D3C290-0164-4C2E-BECE-9AF3CFEF676FQ34992715-2B364D85-FD8F-434F-8895-165690E72E8EQ35149760-691DFE20-3FBC-4B48-947B-E28BF1E2225AQ35557533-914299D2-5FA0-4EDE-BAE3-6EEF226E8DB5Q35861270-635441E9-E81B-41E6-9EBA-913D746DBF73Q35917596-F50B5F40-2A75-453A-8001-B91987E7BE94Q35935502-D8334AA3-7FFC-4F06-A845-E7F968BA36DBQ36276817-1DD4D177-54C6-4AF6-9F46-C633120C442BQ36290778-0ACDDA1A-B306-443D-9333-ADE2AF0DE81DQ36438628-21423365-1B42-4F59-A9D4-80E983C4D81BQ36559862-1DD4BA34-314D-4FF4-B2EA-0AFB25DCF497Q36667066-D97AD27B-EFAD-49FF-A03F-D55E4DED8481Q36765305-2D15A1AF-54C6-4CCD-8812-68A63BA25A1FQ36933403-1B404420-25EC-4D7E-9F5A-FB20FB51A73DQ37310564-FE1E8BAF-71C5-47D7-8F12-8C11DE18FE87Q37335699-DB20C858-C297-4980-8300-77C41EBBEB28Q37336496-917AE33E-FA8F-4A63-BC77-30F10C7FEC5FQ37547199-9787F509-E7B9-4FE0-A1F2-3ECA0D3CF660Q37699395-45AA88DE-DD8B-4C06-95E3-A146CD01F5A7Q37713053-39CCED09-26CA-4295-8D54-E4D58B0AD617Q37975543-AA7E9A17-8D33-4403-A931-3CDF2604598BQ38155123-A11F53AE-1A19-4FE5-9489-ADF74550B787Q38286335-2361C891-B148-41D5-8B0B-E75A53BA53FFQ38581478-88544E53-B0F4-439C-8FFA-A4893F0150FC
P2860
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@en
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@nl
type
label
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@en
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@nl
prefLabel
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@en
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@nl
P2093
P1433
P1476
Recombinant HCV variants with ...... nhibitor but not interferon-α.
@en
P2093
Lotte S Mikkelsen
Tanja B Jensen
Troels K H Scheel
P304
P356
10.1053/J.GASTRO.2010.11.036
P407
P577
2010-11-25T00:00:00Z